You searched for Cybin - Page 46 of 60

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world’s leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event”

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial”

QualityStocksNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom joined LeBron … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People”

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector

Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough … Continue reading “Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector”

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reiterates Engaging Lineup for Its Two-Day Immersive Edutainment Experience – Meet Delic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today reiterated the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part at its two-day premier Meet Delic psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reiterates Engaging Lineup for Its Two-Day Immersive Edutainment Experience – Meet Delic”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan Tryp executives have been meeting with investors at select conferences recently … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial”

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.”

Site Search

Company Search

Search Results for: Cybin